US 6,982,278 B2 | ||
Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | ||
Dawn Alisa Brooks, Indianapolis, Ind. (US); Scott Eugene Conner, Elizabethtown, Ind. (US); Samuel James Dominianni, Indianapolis, Ind. (US); Alexander Glenn Godfrey, Mooresville, Ind. (US); Lynn Stacy Gossett, Indianapolis, Ind. (US); Christopher John Rit, Martinsville, Ind. (US); Allie Edward Tripp, Indianapolis, Ind. (US); Alan M. Warshawsky, Carmel, Ind. (US); Leonard Larry Winneroski, Jr., Greenwood, Ind. (US); and Guoxin Zhu, Noblesville, Ind. (US) | ||
Assigned to Eli Lilly and Company, Indianapolis, Ind. (US) | ||
Appl. No. 10/343,474 PCT Filed Aug. 23, 2001, PCT No. PCT/US01/22615 § 371(c)(1), (2), (4) Date Jan. 29, 2003, PCT Pub. No. WO02/18355, PCT Pub. Date Mar. 07, 2002. |
||
Claims priority of provisional application 60/227233, filed on Aug. 23, 2000. | ||
Prior Publication US 2004/0024034 A1, Feb. 05, 2004 | ||
Int. Cl. A61K 31/421 (2006.01); C07D 263/30 (2006.01) |
U.S. Cl. 514—374 | 32 Claims |
1. A compound represented by the following structural formula: ![]() and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:
![]() is a polymethylene chain, which is saturated or may contain a carbon-carbon double bond;
n is 2, 3, or 4;
W is O or S;
R1 is an unsubstituted or substituted group selected from aryl, heteroaryl, cycloalkyl, aryl-C1-C4 alkyl, heteroaryl-C1-C4
alkyl or cycloalkyl-C1-C4 alkyl;
R2 is H, C1-C4 alkyl or C1-C4 haloalkyl;
Y is an unsubstituted or substituted group selected from phenylene, naphthylene or 1,2,3,4 tetrahydronaphthylene;
R3 is C1-C6 alkyl or C1-C6 haloalkyl;
R4 is H, C1-C10 alkyl, C1-C10 haloalkyl, or a substituted or unsubstituted benzy; and
R5 is H, C1-C4 alkyl or aminoalkyl.
|